Clinical Trial Search

Primary: Number With Observed Adverse Side Effects — 26; 25; 15; 14 participants

Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume

Primary: Percent of Ki-67 Positive Cells — .4023; .5872; .3732; .5035 percentage of stained tumor cell nuclei

Primary: Rate of Dose Limiting Toxicity (DLT) — 17 % participants w severe toxicity

Primary: Proportion of Patients With a Reportable Genetic Variant — 0.61 proportion of participants

Primary: Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase — 18.8; 8.3; 0.0 Percentage of Patients

Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability

Primary: Safety: Number of Participants With Freedom From Device and Procedure-related Major Adverse Events — 18 Participants — p=0.1309

Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale

Primary: Number of Participants With Adverse Events Due to MSOT Imaging — 0 Participants

Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants

Primary: Comparison of Immune Responses of Vaccine+R848 to Vaccine Alone

Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 2; 0; 2 Participants

Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants

Primary: Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During…

Primary: Objective Response Rate (ORR) — 0; 1; 1; 4 Participants

Primary: MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery — 333.7; 105.1 fmol/mg of proteins — p=0.09

Primary: Number of Participants Experiencing the Incidence of Grade One or Higher Adverse Events — 12 participants

Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants

Primary: Overall Survival — 19 months

Primary: Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants

Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants

Primary: Response Rate (RR) — 1 Participants

Primary: Confirmed Response Rate — 10; 14 percentage of participants

Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change

Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…

Primary: Tumor Volume — 93.55 cm^3

Primary: Sensitivity and Specificity of Tozuleristide Fluorescence to Detect Tumor in Equivocal (Ambiguous) Tissue During Surgery When Imaged With the Canvas System — 79.8; 34.7…